News

SAB BIO to Showcase Innovative Diabetes Treatment Approach

SAB BIO to Showcase Innovative Diabetes Treatment Approach

SAB BIO to Present Groundbreaking Diabetes Treatment

MIAMI – SAB BIO (Nasdaq: SABS), a leading clinical-stage biopharmaceutical company, is making strides in developing an innovative immunotherapy for type 1 diabetes (T1D). This promising treatment utilizes a human anti-thymocyte immunoglobulin (hIgG) aimed at delaying the onset or slowing the progression of this complex condition.

Presentation at the EASD Annual Meeting

On September 9, 2024, SAB BIO will showcase its work at the significant 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid. The session, led by Alexandra Kropotova, MD, MBA, who is the Executive Vice President and Chief Medical Officer at SAB, will feature a pivotal presentation titled “Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142.” This presentation will provide essential insights into their advanced immunotherapy strategy.

Event Details

The EASD Annual Meeting, taking place in the Beijing Hall during the INNODIA EASD Symposium at 8:45 am, is one of the foremost global gatherings focused on diabetes research and treatment. It draws thousands of delegates, including experts who come together to explore the latest advancements and possibilities in diabetes care.

What is SAB-142?

SAB-142 represents a cutting-edge therapeutic option designed to serve as a human equivalent to rabbit anti-thymocyte globulin (ATG). This innovative treatment departs from traditional models by employing a low dosage of a human antibody, which significantly reduces the risk of severe immune reactions compared to its rabbit-derived counterpart. Clinical studies have shown that a single modest dose of rabbit ATG can effectively modulate the immune response, slowing the damaging progression of T1D by preserving the function of pancreatic beta cells.

How Does It Work?

The action of SAB-142 targets the immune cells that attack insulin-producing beta cells. By intervening at this critical point, the therapy aims to protect the body's ability to produce insulin, a vital hormone for regulating blood sugar levels. Unlike rabbit ATG, which can lead to serum sickness and immune responses like the production of anti-drug antibodies, SAB-142's human-derived antibodies strive for safer and more consistent treatment over time, which can enhance patient compliance and improve therapy outcomes.

About SAB BIO

SAB BIO is at the forefront of advancements in the biopharmaceutical field, committed to addressing significant unmet medical needs in immune and autoimmune disorders. By employing innovative genetic engineering techniques to develop their Transchromosomic (Tc) Bovine™ platform alongside the DiversitAb™ drug development system, SAB BIO is uniquely positioned to produce a diverse range of multi-targeted, high-potency immunoglobulins (IgGs). This groundbreaking production model eliminates the historical reliance on human donors or convalescent plasma, paving the way for new treatment possibilities for conditions like T1D.

Contacts

For media inquiries, please reach out to: Media Relations:
khollon@sab.bio

For investor relations, please contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com

Frequently Asked Questions

What is SAB-142?

SAB-142 is a human immunotherapy designed to protect pancreatic beta cells, helping to delay the progression of type 1 diabetes.

When will SAB BIO present at the EASD Annual Meeting?

SAB BIO is set to present on September 9, 2024, during the INNODIA EASD Symposium in Madrid.

Who is leading the presentation at EASD?

The presentation will be led by Dr. Alexandra Kropotova, who serves as the Executive Vice President and Chief Medical Officer of SAB BIO.

How does SAB-142 differ from rabbit ATG?

SAB-142 is human-derived, which minimizes the risk of allergic reactions and allows for safer re-dosing compared to rabbit ATG, which can provoke severe immune responses.

How is SAB BIO addressing treatment for T1D?

SAB BIO is developing innovative treatments that utilize advanced technologies to target and preserve insulin-producing cells, fundamentally transforming the management of type 1 diabetes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 4

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 4

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 8

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 6

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 4

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 5

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading

Top 5 Most Recently Viewed Articles

AmpliTech Group Reports Strong Growth and Future Prospects

Updated Category News Views 108

AmpliTech Sees Remarkable Surge in September Bookings AmpliTech Group, Inc. (NASDAQ: AMPG), recognized for its advancements in signal processing systems, has revealed impressive bookings that exceeded $1 million in September. This notable growth not only showcases an increase in client interactions but also highlights a vibrant industry environment fueled by progress in...

Continue Reading
Understanding the Trends in XPO's Short Selling Activity

Updated Category News Views 147

XPO's Rising Short Interest: An Overview XPO's short percent of float has seen a significant rise of 28.32% since the last report, indicating a growing interest in short selling against the company. As of the latest update, the company has reported a total of 6.76 million shares sold short, representing 6.66% of all shares available for trading. Given its trading volume,...

Continue Reading
Celebrating a Decade: Dumpsters.com Launches New Program

Updated Category News Views 147

Dumpsters.com Marks a Decade of Success Dumpsters.com is proudly celebrating ten years of transforming the waste removal industry. Over the past decade, the company has redefined how homeowners, contractors, and businesses tackle dumpster rentals. Since its inception, Dumpsters.com has been on a mission to enhance customer experience, becoming the go-to choice for waste...

Continue Reading
Bond Markets React Positively to New Treasury Secretary's Choice

Updated Category News Views 120

Market Reactions to Treasury Secretary Appointment In a significant development, U.S. Treasuries have experienced a rally, boosting investor confidence. This shift comes on the heels of Scott Bessent's selection as the new Treasury Secretary, a decision that many believe will influence economic policies positively. Bessent is expected to adopt a balanced approach,...

Continue Reading
American Airlines Highlights Its Financial Future at Major Event

Updated Category News Views 123

American Airlines Positioned for Growth at Upcoming Conference As one of the largest airlines globally, American Airlines Group Inc. (NASDAQ: AAL) is set to showcase its financial strength and strategic direction at the upcoming Wolfe Research Global Transportation & Industrials Conference. Chief Financial Officer, Devon May, will represent the company during this...

Continue Reading